Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,301 papers from all fields of science
Search
Sign In
Create Free Account
Anti-HER3 Monoclonal Antibody LJM716
Known as:
LJM716
A human monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. Anti…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
NCIt Antineoplastic Agent Terminology
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
[Preparation and identification of single-chain fragment variable against epidermal growth factor receptor 3].
Mengmiao Liu
,
Peiyan He
,
Biyan Wen
,
Chuangnan Qiu
,
Huangjin Li
,
Lin Zhao
Xi bao yu fen zi mian yi xue za zhi = Chinese…
2019
Corpus ID: 208956383
Objective To express, purify and identify the single-chain fragment variable (scFv) against human epidermal growth factor…
Expand
2017
2017
Abstract P6-12-09: Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression
L. Schwarz
,
K. Hutchinson
,
+11 authors
C. Arteaga
2017
Corpus ID: 79292000
Background: Amplification/overexpression of ERBB receptors and/or ligands has been associated with resistance to anti-HER2…
Expand
2015
2015
Abstract OT3-1-05: Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
P. Shah
,
S. Chandarlapaty
,
+8 authors
S. Modi
2015
Corpus ID: 70573418
Background: Breast cancers that overexpress the human epidermal growth factor receptor 2 (HER2+) are driven by HER2/HER3/PI3K…
Expand
2015
2015
Abstract 5421: HER3 inhibition has little efficacy on hepatocellular carcinoma cell lines
Yong-Shi Li
,
Y. Shao
,
Hanxiao Wang
,
A. Cheng
,
Chih-Hung Hsu
2015
Corpus ID: 73848024
Background: HER3 is a member of the ErbB family of receptor tyrosine kinases that are involved in the pathogenesis of many…
Expand
2014
2014
A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.
K. Reynolds
,
D. Juric
,
+16 authors
Y. Bang
2014
Corpus ID: 59287858
2517 Background: The HER3 receptor is important for maintenance of EGFR- and HER2-driven cancers and targeted therapy resistance…
Expand
2014
2014
Abstract 2612: ljm716, an anti her3 antibody that inhibits her3 dimerization, displays anti-tumor activity in esophageal squamous cell cancer
Q. Sheng
,
Huiqin Wang
,
+7 authors
A. Huang
2014
Corpus ID: 70979727
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Esophageal cancer is the eighth most common…
Expand
2014
2014
Abstract LB-237: Targeting HER3 and IGF1R in NRG1 high lung squamous cell carcinoma
Q. Sheng
,
Maria C. Pinzon-Ortiz
,
R. Das
,
A. Huang
,
X. Rong
,
Z. Cao
2014
Corpus ID: 72057960
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA HER3 is a member of the ErbB family of receptor tyrosine…
Expand
2013
2013
Abstract 4261: Targeting HER3 and PI3K in head and neck squamous cancer cells.
Q. Sheng
,
Huiqin Wang
,
+6 authors
A. Huang
2013
Corpus ID: 71575714
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: Head and neck squamous cell carcinoma…
Expand
2013
2013
Therapeutics , Targets , and Chemical Biology Combination of Antibody That Inhibits Ligand-Independent HER 3 Dimerization and a p 110 a Inhibitor Potently Blocks PI 3 K Signaling and Growth of HER 2…
2013
Corpus ID: 33925111
We examined the effects of LJM716, an HER3 (ERBB3) neutralizing antibody that inhibits ligand-induced and ligand-independent HER3…
Expand
2013
2013
Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors .
J. Garrett
,
Cammie R. Sutton
,
+4 authors
C. Arteaga
2013
Corpus ID: 75513465
We hypothesized that complete inhibition of HER3 is required for the optimal action of HER2 or PI3K/Akt inhibitors against HER2…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE